Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter

IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

See all formats and pricing
More options …
Volume 57, Issue 7


Free PAPP-A as a biomarker: heparin-induced release is not related to coronary atherosclerotic burden

Emilia Tuunainen / Teemu Maaniitty / Juhani Knuuti / Kim Pettersson / Saara Wittfooth / Antti Saraste
  • Turku PET Centre and Heart Center, University of Turku and Turku University Hospital, Turku, Finland
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2018-11-09 | DOI: https://doi.org/10.1515/cclm-2018-1062


  • 1.

    Bayes-Genis A, Conover CA, Overgaard MT, Bailey KR, Christiansen M, Holmes DR, et al. Pregnancy-associated plasma protein a as a marker of acute coronary syndromes. N Engl J Med 2001;345:1022–9.PubMedCrossrefGoogle Scholar

  • 2.

    Harrington SC, Simari RD, Conover CA. Genetic deletion of pregnancy-associated plasma protein-A is associated with resistance to atherosclerotic lesion development in apolipoprotein E-deficient mice challenged with a high-fat diet. Circ Res 2007;100:1696–702.PubMedWeb of ScienceCrossrefGoogle Scholar

  • 3.

    Tuunainen E, Lund J, Danielsson J, Pietilä P, Wahlroos V, Pudge K, et al. Direct immunoassay for free pregnancy-associated plasma protein A (PAPP-A). J Appl Lab Med 2018;3:438–49.CrossrefGoogle Scholar

  • 4.

    Lund J, Wittfooth S, Qin QP, Ilva T, Porela P, Pulkki K, et al. Free vs total pregnancy-associated plasma protein A (PAPP-A) as a predictor of 1-year outcome in patients presenting with non-ST-elevation acute coronary syndrome. Clin Chem 2010;56:1158–65.Web of ScienceCrossrefPubMedGoogle Scholar

  • 5.

    Laursen LS, Overgaard MT, Weyer K, Boldt HB, Ebbesen P, Christiansen M, et al. Cell surface targeting of pregnancy-associated plasma protein A proteolytic activity. Reversible adhesion is mediated by two neighboring short consensus repeats. J Biol Chem 2002;277:47225–34.CrossrefPubMedGoogle Scholar

  • 6.

    Tertti R, Wittfooth S, Porela P, Airaksinen KE, Metsärinne K, Pettersson K. Intravenous administration of low molecular weight and unfractionated heparin elicits a rapid increase in serum pregnancy-associated plasma protein A. Clin Chem 2009;55:1214–7.Web of SciencePubMedCrossrefGoogle Scholar

  • 7.

    Wittfooth S, Tertti R, Lepantalo M, Porela P, Qin Q-P, Tynjala J, et al. Studies on the effects of heparin products on pregnancy-associated plasma protein A. Clin Chim Acta 2011;412:376–81.Web of ScienceCrossrefPubMedGoogle Scholar

  • 8.

    Jespersen CH, Vestergaard KR, Schou M, Teisner B, Iversen K. The effect of heparin on pregnancy associated plasma protein-A concentration in healthy, non-pregnant individuals. Clin Biochem 2015;48:757–61.PubMedCrossrefWeb of ScienceGoogle Scholar

  • 9.

    Uusitalo V, Kamperidis V, de Graaf MA, Maaniitty T, Stenstrom I, Broersen A, et al. Coronary computed tomography angiography derived risk score in predicting cardiac events. J Cardiovasc Comput Tomogr 2017;11:274–80.PubMedWeb of ScienceCrossrefGoogle Scholar

  • 10.

    Hjortebjerg R. IGFBP-4 and PAPP-A in normal physiology and disease. Growth Horm IGF Res 2018;41:7–22.PubMedWeb of ScienceCrossrefGoogle Scholar

About the article

Corresponding author: Emilia Tuunainen, M.Sc., Department of Biochemistry/Biotechnology, University of Turku, Kiinamyllynkatu 10, Medisiina D, 6th Floor, FI-20520 Turku, Finland, Phone: +358 29 450 4596

Received: 2018-09-27

Accepted: 2018-10-18

Published Online: 2018-11-09

Published in Print: 2019-06-26

Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: This work was supported by The Academy of Finland Centre of Excellence on Cardiovascular and Metabolic Disease, Helsinki, Finland (AS and JK), the Finnish Foundation for Cardiovascular Research (AS and JK) and University of Turku Doctoral Programme of Clinical Research (ET). For TM, KP and SW none declared.

Employment or leadership: None declared.

Honorarium: Outside the submitted work consultancy for GE Healthcare, Novartis and Astra Zeneca (AS), payment for lectures from Bayer, Abbott and Actelion (AS) and personal fees from Astra Zeneca (JK). For ET, TM, KP and SW none declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), Volume 57, Issue 7, Pages e155–e158, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm-2018-1062.

Export Citation

©2018 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Comments (0)

Please log in or register to comment.
Log in